News
Frédéric PELONG, Chief Financial Officer, Joins the Valbiotis Board of Directors
Regulatory News:
Valbiotis (FR0013254851 - ALVAL, PEA/SME eligible) (Paris:ALVAL), a Research and Development company committed to scientific innovation for preventing and combating metabolic and
Frédéric PELONG, Chief Financial Officer, wird Vorstandmitglied bei Valbiotis
Valbiotis (FR0013254851 - ALVAL, PEA/KMU-qualifiziert) (Paris: ALVAL), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlichen Innovationen zur Vorbeugung und Bekämpfung
Pharnext Appoints Dr. Rob Quinn as Chief Financial Officer
Pharnext Announces a €2.5m Loan Agreement with Néovacs
Condor Technologies nimmt den Handel an der Börse Euronext in Paris wieder auf
Wir freuen uns, Ihnen die Wiederaufnahme des Handels von Condor Technologies (MLMFI.PA) am 23. August an der Euronext Access Exchange in Paris mitteilen zu dürfen.
Die Wiederaufnahme des Handels
Condor Technologies to Reopen Trading on the Euronext Exchange in Paris
We are pleased to announce the reopening of the trading sessions on August 23rd for Condor Technologies (MLMFI.PA) on the Euronext Access Exchange in Paris.
The resumption of the trading
Valbiotis meldet den Abschluss der Rekrutierung für die klinische Phase II/III-Studie REVERSE-IT mit TOTUM•63 gegen Prädiabetes in Partnerschaft mit Nestlé Health Science
Valbiotis (FR0013254851 - ALVAL, PEA/KMU-qualifiziert) (Paris:ALVAL), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung von
Valbiotis Announces Completion of Recruitment for the Phase II/III REVERSE-IT Clinical Study With TOTUM•63 Against Prediabetes, in Partnership With Nestlé Health Science
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible) (Paris:ALVAL), a Research and Development company committed to scientific innovation for preventing and combating metabolic and
Median Technologies: Financial Communication Schedule for the Second Half of 2022
Regulatory News:
Median Technologies (ALMDT) (Paris:ALMDT), announces the publication date for its 2022 half year results and its Q3, 2022 business performance:
Publication
Date
ROCTOOL: H1 2022 revenues: €4.1 million, +41% vs. H1 2021ROCTOOL
Median Technologies Communicates Its Business Indicators for the Second Quarter of 2022
Regulatory News:
Median Technologies (ALMDT:PA) (Paris:ALMDT) today announces its business indicators for the first half of 2022.
Steady growth of revenue
Following record revenues in Q1 2022
Median Technologies to Participate in the 2022 European Congress of Radiology (ECR), July 13 – 17, 2022, Vienna, Austria, with Two Presentations on iBiopsy®
Regulatory News:
Median Technologies (ALMDT) (Paris:ALMDT) announced today that the Company will be participating in the 2022 European Congress of Radiology (ECR), to be held in Vienna, Austria
Median Technologies to host a live webcast and provide a company update on July 12, 2022
Regulatory News:
Median Technologies (ALMDT:PA) announced today that Fredrik Brag, CEO and founder of Median Technologies, will provide a company update on July 12, 2022 at 11:00 am CEST during a
Sensorion to Present at the Gene Therapy Neurological Disorders Europe, CASSS Bioassays Symposium and Cell & Gene Therapy Summit Conferences in July 2022
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Pharnext Appoints Antoine Gravelle as General Counsel
Sensorion Announces Approval in Australia to Initiate Proof of Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation
Regulatory News:
Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Pharnext: Findings on Symptoms Burden of Charcot-Marie-Tooth Disease Type 1A From the ‘Real-World’ Digital Lifestyle Study, CMT&Me, to be Presented at the ICNMD 2022
Sensorion to Participate in the LifeSci Partners 2nd Annual Genetic Medicines Symposium on June 29, 2022
Regulatory News:
Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Pharnext Holds Shareholders Meeting and Appoints Dr. James Kuo to Renewed Board of Directors
Sensorion to Present at the Inner Ear Disorder Therapeutics Summit in June 2022
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Valbiotis meldet bedeutenden Erfolg der klinischen Phase-II-Studie HEART: die patentgeschützte pflanzenbasierte aktive Substanz TOTUM•070 zeigt Wirksamkeit gegen Hypercholesterinämie, einen kardiovaskulären Risikofaktor
Valbiotis (FR0013254851 - ALVAL, PEA/KMU-qualifiziert), ein Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur Vorbeugung und Bekämpfung von Stoffwechsel- und
Valbiotis announces the major success of the Phase II HEART clinical study: the patented plant-based active substance TOTUM•070 proves its efficacy against hypercholesterolemia, a cardiovascular risk factor
Regulatory News:
Valbiotis (FR0013254851 - ALVAL, PEA/SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic diseases
Bryan Garnier & Co Initiates the Coverage of Median Technologies with a “Buy” Recommendation
Regulatory News:
Median Technologies (ALMDT) announces today the publication of an initiation report by Bryan Garnier & Co, a pan-European investment bank focusing on growth companies.
In the
Sensorion to Present at the Gene Therapy Development and Manufacturing Conference in June 2022
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within